Biosimilars, Outsourcing Impact Biopharma Manufacturing Production

The 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production from BioPlan Associates, Inc., provides global analysis of biopharma trends, based on input from 237 biomanufacturers and 164 suppliers in 28 countries.

The 12th Annual Report and survey is the industry’s definitive, quantitative analysis and includes 12 years of biopharma trends analysis and opportunities review, including in-depth coverage of critical issues affecting the industry. This analysis covers trends shaping the industry through 2020.

Covering 12 critical areas, including: industry growth, downstream processing, single use systems, outsourcing, capacity, and quality management and much more, this year the Report looks at Fill Finish operations and its impact on the industry.  The Report also examines trends including mAbs, biosimilars, outsourcing, and disposables that are opening opportunities and challenges to the entire industry. It also compares over time how Western Europe, the U.S., and ROW biomanufacturers differ in demands for new technologies.

In this 497 page Report, global capacity data show the impact of biosimilars, outsourcing, regulatory, as well as downstream processing and single-use devices, and how they are creating growth potential in both capacity and in the number of facilities coming on-line. Capacity utilization remains overall constant across mammalian and microbial systems, according to this year’s respondents.  This will affect:

  • Overall industry growth
  • Opportunities for suppliers to the industry
  • Demand for skilled staff and better technology
  • Regulatory demands on the industry

For more information, visit